CJC-1295 with DAC vs Letrozole
Well Studied vs FDA Approved
synergistic Mechanism-based · 60% Letrozole helps manage estrogen conversion from CJC-1295 with DAC. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 with DAC Letrozole
Weight 3,647.28 Da 285.30 Da
Half-life 6-8 days ~2 days (48 hours)
Chain 30 amino acids —
Type GHRH analog with DAC Nonsteroidal aromatase inhibitor (triazole derivative)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Letrozole
0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) / Every other day (cycle support); daily (breast cancer / fertility)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
Research Evidence
CJC-1295 with DAC Letrozole
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.